Table 1. Main characteristics of studies involved in this meta-analysis of the PPARG Pro12Ala polymorphism and essential hypertension risk.
| First author | Year | Country | Ethnicity | Source of control | Mean age (y) (case/control) | Sample size (case/control) | Cases | Controls | Genotyping methods | MAF (%) | HWE (Y/N) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pro/Pro | Pro/Ala | Ala/Ala | Pro/Pro | Pro/Ala | Ala/Ala | ||||||||||
| Rodríguez-Esparragón FJ | 2003 | Spain | Caucasian | HB | 59±9/ 57±8 | 229/ 212 | 206 | 22 | 1 | 174 | 36 | 2 | PCR-RFLP | 9.43 | Y |
| Horiki M | 2004 | Japan | Asian | HB | -/ - | 205/ 300 | 193 | 12 | 0 | 276 | 24 | 0 | PCR-RFLP | 4.00 | Y |
| Shen D | 2005 | China | Asian | HB | 69.2±13.5/ 67.3±11.7 | 70/ 220 | 66 | 3 | 1 | 206 | 13 | 1 | PCR-RFLP | 3.41 | Y |
| Zhang AP | 2005 | China | Asian | HB | 58.8±10.7/ 56.7±11.2 | 132/ 157 | 128 | 4 | 0 | 148 | 9 | 0 | PCR-RFLP | 2.87 | Y |
| Gouni-Berthold I | 2005 | Germany | Caucasian | HB | 64.6+9.9/ 60.3±11.8 | 255/ 140 | 190 | 57 | 8 | 104 | 32 | 4 | PCR-RFLP | 14.29 | Y |
| Pan HJ | 2007 | China | Asian | PB | 50.83±12.10/ 39.79±9.67 | 177/ 119 | 154 | 23 | 0 | 101 | 18 | 0 | PCR-RFLP | 7.56 | Y |
| Yin RX * | 2008 | China | Asian | PB | 51.2±14.2/ 43.4±15.2 | 287/ 547 | 265 | 17 | 5 | 518 | 24 | 5 | PCR-RFLP | 3.11 | N |
| Yin RXΔ | 2008 | China | Asian | PB | 55.2±12.1/ 43.8±15.2 | 159/ 676 | 153 | 6 | 0 | 629 | 40 | 7 | PCR-RFLP | 3.99 | N |
| Lu ZC | 2008 | China | Asian | PB | 94.5±4.0/ 94.8±4.0 | 478/ 361 | 446 | 31 | 1 | 312 | 48 | 1 | PCR-RFLP | 6.93 | Y |
| Gao L | 2010 | China | Asian | HB | 54.47±16.21/50.08±15.01 | 345/ 137 | 337 | 7 | 1 | 131 | 2 | 4 | PCR-RFLP | 3.65 | N |
| Dong HR | 2012 | China | Asian | HB | 48.60±13.33/ 38.48±10.93 | 124/ 178 | 122 | 2 | 0 | 177 | 1 | 0 | PCR-RFLP | 0.28 | Y |
| Lin Y | 2012 | China | Asian | PB | 52.10±9.87/ 49.04±9.02 | 269/ 551 | 166 | 90 | 16 | 293 | 205 | 50 | TaqMan | 28.22 | Y |
| Zhang XFδ | 2013 | China | Asian | HB | 51.68±9.63/ 51.87±11.18 | 146/ 112 | 125 | 20 | 1 | 101 | 11 | 0 | PCR-RFLP | 4.91 | Y |
| Zhang XF & | 2013 | China | Asian | HB | 51.76±8.36/ 50.31±8.18 | 163/ 178 | 137 | 25 | 1 | 18 | 20 | 0 | PCR-RFLP | 5.61 | Y |
| Chen J | 2014 | China | Asian | PB | 45.05±12.86/ 42.37±11.61 | 144/ 165 | 110 | 33 | 2 | 105 | 53 | 7 | MALDI-TOF-MS | 20.3 | Y |
| Wang G | 2015 | China | Asian | PB | 52.8±16.2/ 51.4±17.6 | 816/ 824 | 536 | 244 | 36 | 426 | 318 | 80 | PCR-RFLP | 29.00 | Y |
| Grygiel-Górniak B | 2015 | Poland | Caucasian | HB | 59.88±5.07/58.59±5.86 | 151/ 120 | 101 | 44 | 6 | 84 | 32 | 4 | TaqMan | 16.67 | Y |
Abbreviations: MAF, minor allelic frequency; HWE, Hardy-Weinberg equilibrium; HB, hospital based; PH, population based; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism
*male subgroup
Δ female subgroup
δ, Hui subgroup
&, Chinese Han subgroup
Y, yes; N, no.